c-RET
c-RET-Inhibitoren zielen auf das RET (Rearranged during Transfection)-Protoonkogen ab, das für eine Rezeptor-Tyrosinkinase kodiert, die an Zellwachstum, Differenzierung und Überleben beteiligt ist. Eine abnormale Aktivierung der RET-Signalübertragung kann zu unkontrollierter Zellproliferation und Resistenz gegen Apoptose führen, was zur Entwicklung von Krebsarten wie medullärem Schilddrüsenkarzinom und nicht-kleinzelligem Lungenkrebs beiträgt. Die Hemmung von c-RET kann Apoptose in Krebszellen induzieren und ist ein vielversprechender Ansatz in der zielgerichteten Krebstherapie. Bei CymitQuimica bieten wir eine Vielzahl hochwertiger c-RET-Inhibitoren zur Unterstützung Ihrer Forschung in den Bereichen Onkologie, Signaltransduktion und Apoptose an.
61 Produkte aus dem Bereich "c-RET" gefunden
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Formel:C23H27F4N3O4SReinheit:99.23%Farbe und Form:SolidMolekulargewicht:517.54Ref: TM-T10624
1mg40,00€2mg54,00€5mg92,00€10mg127,00€25mg208,00€50mg311,00€100mg445,00€1mL*10mM (DMSO)92,00€RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Formel:C38H42N10O3Farbe und Form:SolidMolekulargewicht:686.81QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Formel:C53H54N12O4Farbe und Form:SolidMolekulargewicht:923.07CDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Formel:C29H26N4OMolekulargewicht:446.21066PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formel:C22H22FN5O2Farbe und Form:SolidMolekulargewicht:407.44RET-IN-28
CAS:RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Formel:C26H29N9Farbe und Form:SolidMolekulargewicht:467.57RET-IN-4
CAS:RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Formel:C27H31FN10O2Farbe und Form:SolidMolekulargewicht:546.611RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Farbe und Form:Odour SolidZeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Formel:C56H56F6N8O12Farbe und Form:SolidMolekulargewicht:1147.098RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Formel:C40H44N10OFarbe und Form:SolidMolekulargewicht:680.84Compound TPX-0046
CAS:Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Formel:C21H21FN6O3Reinheit:99.94%Farbe und Form:SoildMolekulargewicht:424.43YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Formel:C58H63F3N12O9Farbe und Form:SolidMolekulargewicht:1129.19BT44
CAS:BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Formel:C28H27F4N3O4SReinheit:99.87%Farbe und Form:SoildMolekulargewicht:577.59Ref: TM-T67733
1mg74,00€5mg160,00€10mg235,00€25mg424,00€50mg635,00€100mg924,00€1mL*10mM (DMSO)188,00€AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Formel:C22H21ClF3N7OReinheit:98%Farbe und Form:SolidMolekulargewicht:491.9RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Formel:C22H22N6OFarbe und Form:SolidMolekulargewicht:386.45RET ligand-1
CAS:RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Formel:C28H24F2N6O3Farbe und Form:SolidMolekulargewicht:530.525Cofetuzumab
CAS:Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.Reinheit:>95%Farbe und Form:LiquidMolekulargewicht:146.7 kDatrans-Pralsetinib
CAS:trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).Formel:C27H32FN9O2Reinheit:98%Farbe und Form:SolidMolekulargewicht:533.6Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFormel:C27H32FN9O2Reinheit:97.88% - 99.8%Farbe und Form:SolidMolekulargewicht:533.6WHI-P180
CAS:WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Formel:C16H15N3O3Reinheit:99.21%Farbe und Form:SolidMolekulargewicht:297.31
